GLP Test Facility

As part of a collaborative project, funded by the German Federal Ministry of Education and Research, a safety study is being conducted to evaluate the toxicity and safety of a small-molecule active ingredient for the treatment of periodontitis. The active ingredient specifically inhibits enzymes of oral germs that are largely responsible for the development of periodontitis and associated secondary diseases. Due to the selective effect, the natural microbiome remains largely unaffected, which can be seen as an advantage over conventional antibiotic-based therapies. The GLP study will create the essential prerequisites for the envisaged clinical trial.

With the ROR2-CAR-T cell therapy, scientists at the University Hospital of Würzburg have developed an immunotherapy that differs from previously approved therapies both in the type of genetic modification and the target antigen addressed. This is now to be transferred to clinical application as part of a project funded by the German Federal Ministry of Education and Research. The GLP-compliant testing for safety and efficacy is an essential prerequisite for the application and implementation of the intended clinical study.

Preclinical trials are underway to investigate a combination painkiller as part of a joint project funded by the German Federal Ministry of Education and Research. The project aims to minimize safety risks before the drug is used for the first time in patients. The preparation combines an opiate with a dendritic nanotransport molecule (nanocarrier). Preclinical investigations are being carried out under GLP conditions into the safety of the drug using appropriate animal models (small animal model, large animal model) at Fraunhofer IZI. Together with the investigational drug’s manufacture under GMP conditions by the company DendroPharm, the prerequisites are met for the developed drug to then be investigated in a phase I clinical trial at the Fraunhofer Institute for Toxicology and Experimental Medicine. The safety and tolerability of the drug will also be tested on healthy human subjects in single and multiple ascending doses. This marks a further step towards the market maturity of a potential, new pain medication.

In two pre-clinical study arms, the systemic toxicity of the therapeutic vaccines, on the one hand, and the immuno-toxicity, on the other, are assessed in the relevant disease model in mice. This is to be used to examine potential toxic side-effects of the individual vaccine components (HBV peptides, adjuvants, MVA vector) in the event of a repeated maximum dose under an established vaccination schedule, with the help of histopathological, haematological and clinical-chemical analyses. The relevant murine disease model (which imitates chronic hepatitis) is aimed at evaluating immunotoxic effects, on the one hand, and to confirm the effectiveness of the vaccines, on the other.

Since this novel product is a medical product of risk class III, preclinical and clinical examinations have to be carried out under the German medical products law in order to ensure its biological safety.

These safety checks were carried out at the GKP testing facility of the Fraunhofer IZI based on DIN EN ISO 10993. During these examinations, reduction studies were carried out in order to characterise the individual degradation products of the resorbable implant. Furthermore, according to DIN EN ISO 10993-5, the cytotoxic potential of the framework structure was examined in vitro. Systemic toxicity and the local effects after implantation were evaluated in the mouse, using histopathological, haematological and clinical-chemical analyses. In addition to safety, the implantation strategy is also established in Göttingen minipigs under GLP-analogue conditions in order to guarantee the functionality and, ultimately, a low-complication rate application in patients.

The development of novel therapies, such as the somatic cell therapy or the transplantation of tissues generated from stem cells, requires new preclinical strategies as to the safety of these products. Conventional efficacy and safety studies, e.g. for biopharmaceuticals, are not suitable for these cell-based products (cell-based advanced therapy medicinal products; ATMPs). The application of cell-based ATMPs thus requires clearly defined safety studies under GLP (Good Laboratory Practice) conditions that are in line with regulatory requirements of the national and european authorities. Here, the interest mainly focusses on biodistribution, i.e. distribution of the applied cell-based ATMPs within the tissue, as well as tumorigenicity, i.e. the propensity of the applied cells to undergo transformation, and thus have to be appropriately addressed in preclinical studies. The aim of this project is the realization of preclinical efficacy and safety studies for a cartilage therapy on the basis of mesenchymal stem cells (MSC). For this ATMP, MSC are isolated in an out-patient bone marrow aspiration and further treated for the production of a patient-specific cartilage therapy (MSC-based Matrix-associated Autologous Chondrocyte Transplantation; MSC-MACT). In the preclinical GLP studies, both the biodistribution and tumorigenic potential of the human MSC-MACT are tested in immunodeficient mice. Due to the immunodeficiency of the animals, the implanted human cells are tolerated without graft rejection, and the migration and/or transformation of the human cells can be analyzed. For an optimal function of the ATMPs, the MSC should remain at the site of implantation and not migrate into the surrounding tissue. Thus, the experimental "biodistribution" part clarifies whether cells migrate from the site of implantation and where they settle in the case of migration. This simultaneously identifies potential sites of tumorigenesis that can arise from implanted cells. In the subsequent experimental part, tumorigenicity of the MSC from the implanted ATMP is tested. The non-clinical safety studies for MSC-MACT are an important regulatory building block on the way to a clinical application, which may significantly reduce the risks of a therapy with MSC-MACT for patients with cartilage defects.

• Differential protein-biochemical and serological analysis of UV-irradiated and non-irradiated canine thrombocyte concentrates
• Immunotoxicological in-vitro study of the plant-based immunostimulant mistellectin with intestinal epithelial cells
• Safety and efficacy studies of MSC-generated cartilage products after autologous implantation in a large animal model (sheep)
• Safety and efficacy studies of MSC-generated chondrocyte spheroids after implantation in a large animal model (sheep)
• Preclinical safety study for evaluating the biodistribution and tumorigenicity of tissue-engineered human chondrocyte spheroids in an NSG mouse model
• GLP-compliant testing of an allogenic, matrix-associated cell transplant from mesenchymal stroma cells from umbilical cord tissue
• Pre-clinical GLP study to review the safety of a CAR-T cell therapy targeting the Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) in an NSG mouse model